Related Experiment Video

Updated: Aug 8, 2026

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

Targeting the ERK signaling pathway in cancer therapy

Michiaki Kohno1, Jacques Pouyssegur

  • 1Laboratory of Cell Regulation, Department of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Bunkyo-machi, Japan. kohnom@net.nagasaki-u.ac.jp

Annals of Medicine
|May 25, 2006
PubMed

Insights

Targeting the extracellular signal-regulated kinase (ERK) pathway with inhibitors offers a promising strategy for cancer treatment. Combining these cytostatic agents with conventional cytotoxic drugs may lead to novel chemotherapeutic approaches.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The extracellular signal-regulated kinase (ERK) pathway regulates critical cellular functions including proliferation and survival.
  • Aberrant ERK pathway signaling is frequently observed in human cancers, making it a key therapeutic target.
  • Inhibition of the ERK pathway is anticipated to yield anti-proliferative, anti-metastatic, and anti-angiogenic effects.

Purpose of the Study:

  • To review the role of the ERK pathway in cancer.
  • To discuss small-molecule inhibitors targeting the ERK pathway that have entered clinical trials.
  • To explore the potential of combining ERK pathway inhibitors with conventional chemotherapy.

Main Methods:

  • Literature review of ERK pathway inhibitors and their clinical development.
  • Discussion of the therapeutic rationale for targeting the ERK pathway in oncology.
  • Exploration of combination strategies involving ERK inhibitors and cytotoxic agents.

Main Results:

  • Several potent small-molecule inhibitors targeting ERK pathway components (Raf, MEK1/2) have been developed.
  • Inhibitors such as BAY 43-9006, PD184352, PD0325901, and ARRY-142886 are in clinical trials.
  • The combination of ERK pathway inhibitors with conventional anticancer drugs is proposed as a viable chemotherapeutic strategy.

Conclusions:

  • Targeting the ERK pathway is a promising strategy for developing new anticancer drugs.
  • ERK pathway inhibitors demonstrate potential for anti-proliferative, anti-metastatic, and anti-angiogenic activities.
  • Combination therapy of ERK inhibitors and cytotoxic agents offers a strong foundation for novel cancer treatment strategies.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...